Significance of the EU Marketing Authorisation Renewal Process

Merck & Co.'s (MRK) 15-valent pneumococcal conjugate vaccine (PCV15), Vaxneuvance, has entered the European Medicines Agency's (EMA) five-year marketing authorisation renewal and revision process. This renewal process, initiated after the initial approval on December 13, 2021, is a standard procedure to ensure long-term supply stability in Europe based on accumulated clinical safety and efficacy data. The regulatory agency's thorough periodic validation will further solidify the credibility of Vaxneuvance among healthcare professionals and patients. This establishes a strong regulatory foundation, enabling the vaccine to remain a key component in public health immunization programs.

Analysis of the Competitive Landscape in the Multivalent Vaccine Market

The global pneumococcal vaccine market currently ranges from approximately $8 billion to $10.6 billion, with intense competition for market share between Pfizer's (PFE) Prevnar 13 and Prevnar 20 (marketed as Apexxnar in Europe). Merck has been accelerating its market penetration with Vaxneuvance, breaking Pfizer's long-standing monopoly and leveraging its ability to induce precise immune memory targeting 15 serotypes. Furthermore, the company has strategically expanded its portfolio by recently receiving approval for Capvaxive, a 21-valent vaccine for adults. This renewal and revision of Vaxneuvance's approval serve as an essential defense mechanism for Merck to protect its market share in Europe against Pfizer's Prevnar franchise and strengthen its pipeline competitiveness.

Continued Expansion of Indications for Pediatric and Adult Use

Following its initial approval for adults, Vaxneuvance successfully expanded its indication to include infants and young children aged six weeks and older in October 2022, driving revenue growth. The vaccine's inclusion of serotypes 22F and 33F, which are important for preventing invasive pneumococcal disease (IPD) and acute otitis media, has been a key differentiator in the pediatric immunization market. Obtaining regulatory approval is a prerequisite for securing bids in national immunization programs (NIP), making this renewal process crucial. With the long-term clinical safety profile confirmed, it is expected that the adoption of Vaxneuvance as a national essential immunization by health authorities in various countries will be further facilitated.

Excellence of Conjugate Vaccine Technology and Market Impact

This vaccine is developed using innovative conjugate vaccine technology, which physically binds pneumococcal polysaccharide antigens to the protein carrier CRM197. Compared to simple polysaccharide vaccines, it elicits a much stronger immune response and effectively activates memory B cells, providing long-term protective effects. This technological advantage has enabled Merck, despite being a late entrant in the global vaccine market, to secure large-scale government procurement contracts. With the overall pneumococcal vaccine market expected to grow to over $12 billion by 2030, Vaxneuvance is poised to become a key cash cow, supporting Merck's long-term cash flow in the vaccine business.